Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Trends in Immunology
|
December 8, 2019
Stem, Effector, and Hybrid States of Memory CD8<sup>+</sup> T Cells
Enrico Lugli, Giovanni Galletti, Shannon K Boi, et al.
Cold Spring Harbor Perspectives in Biology
|
June 15, 2021
Defining the Molecular Hallmarks of T-Cell Memory
Caitlin C Zebley, Rama S Akondy, Benjamin A Youngblood, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 20, 2013
Global DNA methylation remodeling accompanies CD8 T cell effector function
Christopher D Scharer, Benjamin G Barwick, Benjamin A Youngblood, et al.
The Journal of Experimental Medicine
|
March 5, 2014
Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection
Peiyuan Lu, Benjamin A Youngblood, James W Austin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Maria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Nature Reviews. Immunology
|
October 2, 2019
Defining 'T cell exhaustion'
Christian U Blank, W Nicholas Haining, Werner Held, et al.
Science Translational Medicine
|
June 28, 2019
Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8<sup>+</sup> T cell responses
Anthony E Zamora, Jeremy Chase Crawford, E Kaitlynn Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, et al.
Blood Neoplasia
|
June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS
H Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2024
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS
H Josh Jang, Guillermo Urrutia, Andreas Due Orskov, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Trends in Immunology
|
December 8, 2019
Stem, Effector, and Hybrid States of Memory CD8<sup>+</sup> T Cells
Enrico Lugli, Giovanni Galletti, Shannon K Boi, et al.
Cold Spring Harbor Perspectives in Biology
|
June 15, 2021
Defining the Molecular Hallmarks of T-Cell Memory
Caitlin C Zebley, Rama S Akondy, Benjamin A Youngblood, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 20, 2013
Global DNA methylation remodeling accompanies CD8 T cell effector function
Christopher D Scharer, Benjamin G Barwick, Benjamin A Youngblood, et al.
The Journal of Experimental Medicine
|
March 5, 2014
Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection
Peiyuan Lu, Benjamin A Youngblood, James W Austin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Maria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Nature Reviews. Immunology
|
October 2, 2019
Defining 'T cell exhaustion'
Christian U Blank, W Nicholas Haining, Werner Held, et al.
Science Translational Medicine
|
June 28, 2019
Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8<sup>+</sup> T cell responses
Anthony E Zamora, Jeremy Chase Crawford, E Kaitlynn Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, et al.
Blood Neoplasia
|
June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS
H Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2024
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS
H Josh Jang, Guillermo Urrutia, Andreas Due Orskov, et al.
Page
of 2